Rhumbline Advisers Tcr2 Therapeutics Inc. Transaction History

Rhumbline Advisers

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$2.11 - $2.94 $74,134 - $103,296	-35,135 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$2.4 - $4.71 $7,036 - $13,809	-2,932 Reduced 7.7%	35,135 $97,000
Q4 2021 Feb 10, 2022	SELL	$4.58 - $8.34 $2,825 - $5,145	-617 Reduced 1.59%	38,067 $177,000
Q3 2021 Nov 12, 2021	BUY	$8.44 - $18.35 $12,111 - $26,332	1,435 Added 3.85%	38,684 $329,000
Q2 2021 Aug 05, 2021	BUY	$16.41 - $24.71 $6,153 - $9,266	375 Added 1.02%	37,249 $611,000

Q1 2021 May 06, 2021	SELL	$20.38 - $34.07 $203 - $340	-10 Reduced 0.03%	36,874 $814,000
Q4 2020 Feb 10, 2021	BUY	$19.0 - $32.63 $122,227 - $209,908	6,433 Added 21.13%	36,884 $1.14 Million
Q3 2020 Nov 12, 2020	BUY	$13.1 - $20.69 $107,302 - $169,471	8,191 Added 36.8%	30,451 $619,000
Q2 2020 Aug 13, 2020	BUY	$6.51 - $16.85 $64,592 - $167,185	9,922 Added 80.42%	22,260 $342,000
Q1 2020 May 06, 2020	BUY	$6.01 - $16.01 $7,632 - $20,332	1,270 Added 11.47%	12,338 $95,000
Q4 2019 Feb 05, 2020	BUY	$12.17 - $17.88 $3,383 - $4,970	278 Added 2.58%	11,068 $158,000
Q3 2019 Oct 23, 2019	BUY	$10.15 - $19.53 $109,518 - $210,728	10,790 New	10,790 $162,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.